ASH | FDA Collaboration: A Workshop on Regulatory Science in Hematology – Hematology.org
ASH | FDA Collaboration: A Workshop on Regulatory Science in Hematology
ASH | FDA Collaboration: A Workshop on Regulatory Science in Hematology
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study…
Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.
Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.
Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic…
Obstacles along his life’s path made @WexMed Chief Health Equity Officer Chyke Doubeni, MD, MPH, dedicate his career to helping removing barriers so all people,…
Recent research has provided valuable insights into the long-term outcomes of patients with pathogenic BRCA1 and BRCA2 mutations who undergo breast-conserving therapy, according to a…
Rezatapopt induced responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations.
With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast…